Abstract
Background: Problematic high-dose benzodiazepine (BZD) and related Z-drug use for a long period is a substance use disorder previously found to be associated with adult attention-deficit/hyperactivity disorder (ADHD) and worse quality of life (QoL). Whether adult ADHD impacts QoL in high-dose BZD/Z-drug users has not been explored. Aim: The aim of the study was to explore the impact of adult ADHD on QoL in high-dose BZD and related Z-drug users. Methods: We recruited 393 patients (205 men and 188 women) consecutively admitted to the Department of Medicine, Addiction Medicine Unit, Verona University Hospital, Italy, from July 2016 to July 2019 for detoxification from high-dose BZD or Z-drug dependence. Demographic and clinical variables and QoL measures were recorded. The World Health Organization ADHD Self-Report Scale version 1.1 Symptom Checklist Part A was used to detect adult ADHD. Results: In our sample, 39.4% of patients were positive to adult ADHD testing (ADHD+), with some clinical features differing in comparison to patients negative to ADHD testing (ADHD−). QoL was worse in high-dose BZD/Z-drug users than the general population. The ADHD+ group showed significantly worse QoL measures than the ADHD− group. Multivariate analysis, including potential covariates showed adult ADHD and age to have the most robust and consistent positive effect for age (i.e., higher QoL) and negative effect for ADHD (i.e., lower QoL) on QoL measures. Conclusions: Adult ADHD is associated with worse QoL measures in high-dose BZD/Z-drug users. Future studies should explore whether appropriate BZD/Z-drug detoxification might improve QoL measures and whether the most appropriate detoxification protocol differs in ADHD+ versus ADHD− populations.
References
1.
Lader
M
. Benzodiazepines revisited–will we ever learn?
Addiction
. 2011
;106
(12
):2086
–109
. 2.
Soyka
M
. Treatment of benzodiazepine dependence
. N Engl J Med
. 2017
;376
(12
):1147
–57
. 3.
Kurko
TA
, Saastamoinen
LK
, Tähkäpää
S
, Tuulio-Henriksson
A
, Taiminen
T
, Tiihonen
J
, et al Long-term use of benzodiazepines: definitions, prevalence and usage patterns: a systematic review of register-based studies
. Eur Psychiatry
. 2015
;30
(8
):1037
–47
. 4.
Faccini
M
, Leone
R
, Opri
S
, Casari
R
, Resentera
C
, Morbioli
L
, et al Slow subcutaneous infusion of flumazenil for the treatment of long-term, high-dose benzodiazepine users: a review of 214 cases
. J Psychopharmacol
. 2016
;30
(10
):1047
–53
. 5.
Liebrenz
M
, Schneider
M
, Buadze
A
, Gehring
MT
, Dube
A
, Caflisch
C
. High-dose benzodiazepine dependence: a qualitative study of patients’ perceptions on initiation, reasons for use, and obtainment
. PloS One
. 2015
;10
(11
):e0142057
. 6.
Tamburin
S
, Faccini
M
, Casari
R
, Federico
A
, Morbioli
L
, Franchini
E
, et al Low risk of seizures with slow flumazenil infusion and routine anticonvulsant prophylaxis for high-dose benzodiazepine dependence
. J Psychopharmacol
. 2017
;31
(10
):1369
–73
. 7.
Ohayon
MM
, Lader
MH
. Use of psychotropic medication in the general population of France, Germany, Italy, and the United Kingdom
. J Clin Psychiatry
. 2002
;63
(9
):817
–25
. 8.
Petitjean
S
, Ladewig
D
, Meier
CR
, Amrein
R
, Wiesbeck
GA
. Benzodiazepine prescribing to the Swiss adult population: results from a national survey of community pharmacies
. Int Clin Psychopharmacol
. 2007
;22
(5
):292
–8
. 9.
Lugoboni
F
, Mirijello
A
, Faccini
M
, Casari
R
, Cossari
A
, Musi
G
, et al Quality of life in a cohort of high-dose benzodiazepine dependent patients
. Drug Alcohol Depend
. 2014
;142
:105
–9
. 10.
Tamburin
S
, Federico
A
, Faccini
M
, Casari
R
, Morbioli
L
, Sartore
V
, et al Determinants of quality of life in high-dose benzodiazepine misusers
. Int J Environ Res Public Health
. 2017b
;14
(1
):38
. 11.
Federico
A
, Tamburin
S
, Maier
A
, Faccini
M
, Casari
R
, Morbioli
L
, et al Multifocal cognitive dysfunction in high-dose benzodiazepine users: a cross-sectional study
. Neurol Sci
. 2017
;38
(1
):137
–42
. 12.
Polanczyk
G
, Rohde
LA
. Epidemiology of attention-deficit/hyperactivity disorder across the lifespan
. Curr Opin Psychiatry
. 2007
;20
(4
):386
–92
. 13.
Volkow
ND
, Swanson
JM
. Clinical practice: adult attention deficit-hyperactivity disorder
. N Engl J Med
. 2013
;369
(20
):1935
–44
. 14.
Bonvicini
C
, Faraone
SV
, Scassellati
C
. Attention-deficit hyperactivity disorder in adults: a systematic review and meta-analysis of genetic, pharmacogenetic and biochemical studies
. Mol Psychiatry
. 2016
;21
(11
):1643
–84
. 15.
Charach
A
, Yeung
E
, Climans
T
, Lillie
E
. Childhood attention-deficit/hyperactivity disorder and future substance use disorders: comparative meta-analyses
. J Am Acad Child Adolesc Psychiatry
. 2011
;50
(1
):9
–21
. 16.
Lee
SS
, Humphreys
KL
, Flory
K
, Liu
R
, Glass
K
. Prospective association of childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and abuse/dependence: a meta-analytic review
. Clin Psychol Rev
. 2011
;31
(3
):328
–41
. 17.
van de Glind
G
, van den Brink
W
, Koeter
MW
, Carpentier
PJ
, van Emmerik-van Oortmerssen
K
, Kaye
S
, et al Validity of the adult ADHD self-report scale (ASRS) as a screener for adult ADHD in treatment seeking substance use disorder patients
. Drug Alcohol Depend
. 2013
;132
(3
):587
–96
. 18.
van de Glind
G
, Konstenius
M
, Koeter
MWJ
, van Emmerik-van Oortmerssen
K
, Carpentier
PJ
, Kaye
S
, et al Variability in the prevalence of adult ADHD in treatment seeking substance use disorder patients: results from an international multi-center study exploring DSM-IV and DSM-5 criteria
. Drug Alcohol Depend
. 2014
;134
:158
–66
. 19.
van Emmerik-van Oortmerssen
K
, van de Glind
G
, van den Brink
W
, Smit
F
, Crunelle
CL
, Swets
M
, et al Prevalence of attention-deficit hyperactivity disorder in substance use disorder patients: a meta-analysis and meta-regression analysis
. Drug Alcohol Depend
. 2012
;122
(1–2
):11
–9
. 20.
van Emmerik-van Oortmerssen
K
, van de Glind
G
, Koeter
MW
, Allsop
S
, Auriacombe
M
, Barta
C
, et al Psychiatric comorbidity in treatment-seeking substance use disorder patients with and without attention deficit hyperactivity disorder: results of the IASP study
. Addiction
. 2014
;109
(2
):262
–72
. 21.
Lugoboni
F
, Zamboni
L
, Mantovani
E
, Cibin
M
, Tamburin
, S
, Tamburin
S
. Association between adult attention deficit/hyperactivity disorder and intravenous misuse of opioid and benzodiazepine in patients under opioid maintenance treatment: a cross-sectional multicentre study
. Eur Addict Res
. 2020 Jan
; 29
:1
-11
. 22.
Mariani
JJ
, Levin
FR
. Treatment strategies for co-occurring ADHD and substance use disorders
. Am J Addict
. 2007
;16
(Suppl 1
):45
–6
. 23.
Lugoboni
F
, Levin
FR
, Pieri
MC
, Manfredini
M
, Zamboni
L
, Somaini
L
, et al Co-occurring attention deficit hyperactivity disorder symptoms in adults affected by heroin dependence: patients characteristics and treatment needs
. Psychiatry Res
. 2017
;250
:210
–6
. 24.
Rodríguez-Cintas
L
, Daigre
C
, Braquehais
MD
, Palma-Alvarez
RF
, Grau-López
L
, Ros-Cucurull
E
, et al Factors associated with lifetime suicidal ideation and suicide attempts in outpatients with substance use disorders
. Psychiatry Res
. 2018
;262
:440
–5
. 25.
Ahnemark
E
, Di Schiena
M
, Fredman
AC
, Medin
E
, Söderling
JK
, Ginsberg
Y
. Health-related quality of life and burden of illness in adults with newly diagnosed attention-deficit/hyperactivity disorder in Sweden
. BMC Psychiatry
. 2018
;18
(1
):223
. 26.
Liao
YT
, Chen
CY
, Ng
MH
, Huang
KY
, Shao
WC
, Lin
TY
, et al Depression and severity of substance dependence among heroin dependent patients with ADHD symptoms
. Am J Addict
. 2017
;26
(1
):26
–33
. 27.
Tamburin
S
, Federico
A
, Morbioli
L
, Faccini
M
, Casari
R
, Zamboni
L
, et al Screening for adult attention deficit/hyperactivity disorder in high-dose benzodiazepine dependent patients
. Am J Addict
. 2017
;26
(6
):610
–4
. 28.
Kessler
RC
, Adler
L
, Ames
M
, Demler
O
, Faraone
S
, Hiripi
E
, et al The World Health Organization adult ADHD self-report scale (ASRS): a short screening scale for use in the general population
. Psychol Med
. 2005
;35
(2
):245
–56
. 29.
Brazier
JE
, Harper
R
, Jones
NM
, O’Cathain
A
, Thomas
KJ
, Usherwood
T
, et al Validating the SF-36 health survey questionnaire: new outcome measure for primary care
. BMJ
. 1992
;305
(6846
):160
–4
. 30.
Goldberg
DP
, Hillier
VF
. A scaled version of the general health questionnaire
. Psychol Med
. 1979
;9
(1
):139
–45
. 31.
Piccinelli
M
, Bisoffi
G
, Bon
MG
, Cunico
L
, Tansella
M
. Validity and test-retest reliability of the Italian version of the 12-item general health questionnaire in general practice: a comparison between three scoring methods
. Compr Psychiatry
. 1993
;34
(3
):198
–205
. 32.
Chung
W
, Jiang
SF
, Paksarian
D
, Nikolaidis
A
, Castellanos
FX
, Merikangas
KR
, et al Trends in the prevalence and incidence of attention-deficit/hyperactivity disorder among adults and children of different racial and ethnic groups
. JAMA Netw Open
. 2019
;2
(11
):e1914344
. 33.
Adisetiyo
V
, Gray
KM
. Neuroimaging the neural correlates of increased risk for substance use disorders in attention-deficit/hyperactivity disorder-a systematic review
. Am J Addict
. 2017
;26
(2
):99
–111
. 34.
Carpentier
PJ
, Arias Vasquez
A
, Hoogman
M
, Onnink
M
, Kan
CC
, Kooij
JJ
, et al Shared and unique genetic contributions to attention deficit/hyperactivity disorder and substance use disorders: a pilot study of six candidate genes
. Eur Neuropsychopharmacol
. 2013
;23
(6
):448
–57
. 35.
Mitchell
MR
, Potenza
MN
. Addictions and personality traits: impulsivity and related constructs
. Curr Behav Neurosci Rep
. 2014
;1
(1
):1
–12
. 36.
Wilens
TE
, Adamson
J
, Sgambati
S
, Whitley
J
, Santry
A
, Monuteaux
MC
, et al Do individuals with ADHD self-medicate with cigarettes and substances of abuse? Results from a controlled family study of ADHD
. Am J Addict
. 2007
;16
(Suppl 1
):14
–23
. 37.
Faccini
M
, Tamburin
S
, Casari
R
, Morbioli
L
, Lugoboni
F
. High-dose lormetazepam dependence: strange case of Dr. Jekyll and Mr. Hyde
. Intern Emerg Med
. 2019
;14
(8
):1271
–8
. 38.
Young
JT
, Carruthers
S
, Kaye
S
, Allsop
S
, Gilsenan
J
, Degenhardt
L
, et al Comorbid attention deficit hyperactivity disorder and substance use disorder complexity and chronicity in treatment-seeking adults
. Drug Alcohol Rev
. 2015
;34
(6
):683
–93
. 39.
Vogel
T
, Dom
G
, van de Glind
G
, Studer
J
, Gmel
G
, Strik
W
, et al Is attention deficit/hyperactivity disorder among men associated with initiation or escalation of substance use at 15-month follow-up? A longitudinal study involving young Swiss men
. Addiction
. 2016
;111
(10
):1867
–78
. 40.
Katzman
MA
, Bilkey
TS
, Chokka
PR
, Fallu
A
, Klassen
LJ
. Adult ADHD and comorbid disorders: clinical implications of a dimensional approach
. BMC Psychiatry
. 2017
;17
(1
):302
. 41.
Wajszilber
D
, Santiseban
JA
, Gruber
R
. Sleep disorders in patients with ADHD: impact and management challenges
. Nat Sci Sleep
. 2018
;10
:453
–80
. 42.
Wieder-Huszla
S
, Szkup
M
, Jurczak
A
, Samochowiec
A
, Samochowiec
J
, Stanisławska
M
, et al Effects of socio-demographic, personality and medical factors on quality of life of postmenopausal women
. Int J Environ Res Publ Health
. 2014
;11
(7
):6692
–708
. 43.
Andrade
LF
, Alessi
SM
, Petry
NM
. The impact of contingency management on quality of life among cocaine abusers with and without alcohol dependence
. Am J Addict
. 2012
;21
(1
):47
–54
. 44.
Prigent
A
, Auraaen
A
, Kamendje-Tchokobou
B
, Durand-Zaleski
I
, Chevreul
K
. Health-related quality of life and utility scores in people with mental disorders: a comparison with the non-mentally ill general population
. Int J Environ Res Publ Health
. 2014
;11
(3
):2804
–17
. 45.
Astals
M
, Domingo-Salvany
A
, Buenaventura
CC
, Tato
J
, Vazquez
JM
, Martín-Santos
R
, et al Impact of substance dependence and dual diagnosis on the quality of life of heroin users seeking treatment
. Subst Use Misuse
. 2008
;43
(5
):612
–32
. 46.
Lozano
ÓM
, Rojas
AJ
, Fernández Calderón
F
. Psychiatric comorbidity and severity of dependence on substance users: how it impacts on their health-related quality of life?
J Ment Health
. 2017
;26
(2
):119
–26
. 47.
Sjöwall
D
, Thorell
LB
. Neuropsychological deficits in relation to ADHD symptoms, quality of life, and daily life functioning in young adulthood
. Appl Neuropsychol Adult
. 2019
;27
:1
–9
. 48.
Ward
MF
, Wender
PH
, Reimherr
FW
. The Wender Utah rating scale: an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder
. Am J Psychiatry
. 1993
;150
(6
):885
–90
. 49.
Ohlmeier
MD
, Peters
K
, Te Wildt
BT
, Zedler
M
, Ziegenbein
M
, Wiese
B
, et al Comorbidity of alcohol and substance dependence with attention-deficit/hyperactivity disorder (ADHD)
. Alcohol Alcohol
. 2008
;43
(3
):300
–4
. 50.
Martínez-Luna
N
, Daigre
C
, Palma-Álvarez
F
, Perea-Ortueta
M
, Grau-López
L
, Roncero
C
, et al Psychiatric comorbidity and addiction severity differences in patients with ADHD seeking treatment for cannabis or cocaine use disorders
. J Atten Disord
. 2019 Sep 24
:1087054719875787
. Epub ahead of print
.51.
Coghill
DR
, Banaschewski
T
, Soutullo
C
, Cottingham
MG
, Zuddas
A
. Systematic review of quality of life and functional outcomes in randomized placebo-controlled studies of medications for attention-deficit/hyperactivity disorder
. Eur Child Adolesc Psychiatry
. 2017
;26
(11
):1283
–307
. 52.
Apolone
G
, Mosconi
P
. The Italian SF-36 health survey: translation, validation and norming
. J Clin Epidemiol
. 1988
;51
(11
):1025
–36
.© 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
